[1] 扎洛. 血清学指标联合检测评估慢性肾衰竭患者中的应用[J].中国预防医学杂志,2019,20(6):548-550. [2] 蒋慧,丁国华.非透析慢性肾衰竭患者发生心功能不全危险因素分析[J].医学研究杂志,2018,47(3):24-28. [3] 唐利,廖常彬,钟春梅.血清脑钠肽及氨基末端脑钠肽前体在评价慢性肾衰竭患者心功能中的价值[J].临床肾脏病杂志,2016,16(4):215-218. [4] 丁兵. IL-33及可溶性ST2在心力衰竭中的价值和意义[D].苏州:苏州大学,2014. [5] OGNIBENE A, GRANDI G, LORUBBIO M, et al.KDIGO 2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection?[J]. Clin Biochem, 2016, 49(1-2): 85-89. [6] NAKANO Y, MIZUNO T, NIWA T, et al.Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Eventsin Heart Failure Patients with Chronic Kidney Disease[J]. Int Heart J, 2018, 59(1):105-111. [7] 杨树涵,陈红伟,刘艳宾,等.探讨原发性高血压患者血浆sST2浓度与左心功能的关系[J].临床心血管病杂志,2019,35(7):653-656. [8] WANG E W, JIA XS, RUAN C W, et al.miR-487b mitigates chronic heart failure through inhibition of the IL-33/ST2 signaling pathway[J]. Oncotarget, 2017, 8(31):51688-51702. |